President Obama yesterday took the fight for a public healthcare option to a skeptical audience, telling the American Medical Association that a government plan that would compete with private insurers is "not your enemy; it is your friend."

Doctors, hospitals, and other providers worry they would lose money under a government insurance plan if it used the power of its size to dictate payment rates that are much lower than what private insurers pay. That is essentially what Medicare and Medicaid do now, and many providers make up their losses by charging private insurers more.

Below is a sample of entries from the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The companies outlined below have expected FDA new drug product decisions or clinical trial results expected over the next three months of summer. The list also includes some Extreme Trades of companies with market caps below $250 million that have pending clinical trial results or FDA decisions that could have a major stock price impact.

The market experienced broad declines on Monday, hurt by weak economic data- a sharp contrast to last week when the Dow industrials rallied to turn positive for the year- increasing hopes that the economy is starting to turn around. Some key reports issued on Monday helped underscore the fact that the economy is still struggling.

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following additional categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage pivotal Phase 3 clinical trial results which are designed to support a filing for FDA approval.

Approximately 25 percent of strokes are caused by carotid artery disease. In carotid artery disease, arteries located on either side of the neck that supply blood to the brain become narrowed or blocked due to the deposit of fatty plaques that can lead to stroke. Stroke is the third leading cause of death in developed countries, exceeded only by heart disease and cancer.

Below this text an alternate feed of the interview with Dr. William A. Carter of Hemispherx Biopharma:

Dr.William A. Carter, the CEO of Hemispherx Biopharma shares his thoughts on the FDA delay, the flu pandemic and the future of his company. Late in the interview he also answers questions submitted to us by our readers. Certainly, the interview is filled with candid revelations and interesting nuggets of new information.

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage pivotal Phase 3 clinical trial results which are designed to support a filing for FDA approval.

The swine flu crisis has escalated into the world's first influenza pandemic in 40 years, the World Health Organization declared Thursday, saying nearly 30,000 cases had been reported in 74 countries so far. WHO chief Margaret Chan said the UN body would not recommend travel restrictions or the closure of borders, adding that further spread of infection is "inevitable".